In various tumor models, these STAT3 degraders significantly inhibited tumor progression, particularly demonstrating significant synergistic effects in immune checkpoint therapy‐resistant models, showing promising safety profiles and clinical translation potential. Here, STAT3 is linked to neoplasm.